Indication: neuroendocrine tumours

Patients with somatostatin receptors (sstr), especially sstr subtype 2 (sstr2), expressing neuroendocrine tumours of the gastroenteropancreatic and bronchial tract, pheochromocytoma, paraganglioma, neuroblastoma, or medullary thyroid carcinoma.

In general, patients should have one of the following in order to receive peptide receptor radionuclide therapy (PRRT) [46,146]:

• A progressive tumour assessed by anatomical imaging.
• Non-progressive extensive disease in two or more organs, and progressive disease in others site that is likely to be uncontrolled.
• Clinically uncontrollable symptoms using best standard of care.
• Inoperable disease, although surgery can be reconsidered after successful PRRT.